tirzepatide side chain sidechain, 2915356-76-0 D-Gamma-Glu-Side chain]-Tirzepatide | CAS No-

Semaglutide is currently the most prominent approved option in this class: Ozempic (semaglutide injection) licensed for type 2 diabetes management Wegovy (semaglutide 2.4 mg injection) licensed specifically for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity

Antibodies with Advanced Verification data have been validated for specificity to ensure that the antibody binds to the antigen stated

Instruct patients to monitor for new pain or tenderness, sores or ulcers, or infections involving the leg or foot and to seek medical advice immediately if such signs or symptoms develop [see Warnings and Precautions (5.6)]

The mean percentage change in weight at week 72 was 15.0% (95% confidence interval [CI], 15.9 to 14.2) with 5-mg weekly doses of tirzepatide, 19.5% (95% CI, 20.4 to 18.5) with 10-mg doses, and 20.9% (95% CI, 21.8 to 19.9) with 15-mg doses

Schedule your consultation to learn how semaglutide treatment may support structured and medically guided weight management